openPR Logo
Press release

Neuralgia Treatment Market Expected to Witness Rapid Expansion by the End of 2022 With Competition Tracking- Allergan, Merz Pharma GmbH & Co., Biogen, Merz Pharma GmbH & Co., Abbott Laboratories, Trigemina, Pfizer, Novartis, GlaxoSmithKline Plc. F, Lupin

11-13-2018 09:26 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Fact.MR

Fact.MR

Fact.MR

Neuralgia is an abnormal symptom with effects like sharp, burning, and mostly severe pain, due to an irritated or damaged nerve. The causative nerve may be from anywhere in the body, The damage caused by the nerve is associated with several factors like aging, cardiovascular diseases, diabetes, multiple sclerosis, shingles infection, and more. Therefore, Neuralgia Treatment for the pain is directed towards its roots or its site of origin. Potential Neuralgia Treatment may include surgery to relieve the pressure, control of sugar level in the blood of diabetic patients, physical therapy or body massage, epidural injections to 'turn off' pain signals and reduce inflammation directed at a particular nerve or nerve group, and medicinal Neuralgia Treatment to reduce the pain. The Neuralgia Treatment market is driven by the occurrence of common neuralgias such as trigeminal, postherpetic, glossopharyngeal, and occipital neuralgia. More uncommon Neuralgia Treatment may be required for periorbital and auricular neuralgias.

Claim Sample Report For FREE- https://www.factmr.com/connectus/sample?flag=S&rep_id=2282

Neuralgia Treatment Market: Drivers and Restraints

The global Neuralgia Treatment market is primarily driven by the increase in the geriatric population around the world. The disorder is more common in people aged 50 years or more, which drives the Neuralgia Treatment market. Although, it can occur at any age. Adults suffering from multiple sclerosis and diabetes also have a high risk of developing neuralgias, which also significantly contributes to the Neuralgia Treatment market. According to the National Institute of Neurological Disorders and Strokes (NINDS) 2018 report, the incidences of new cases is approximately 12 per 100,000 people per year. The disorder is more common in women than in men. If pain still persists even after conservative Neuralgia Treatment for several months, it is recommended to undergo spine surgery. Neuralgia Treatment involving spine surgery comes with high medical costs, and is unaffordable for people from low income regions such as Asia and Africa, where most people often remain untreated.

Overall, drug-based Neuralgia Treatment therapy will remain the first line of treatment for many, and will contribute majorly to the global Neuralgia Treatment market. However, nerve blocks surgery and other procedures may be necessity in a few cases as far as Neuralgia Treatment is concerned.

Neuralgias Market: Segmentation

Tentatively, the global Neuralgia Treatment market can be segmented on the basis of treatment type, distribution channel, and geography.

Based on treatment type, the global Neuralgia Treatment market is segmented as:

Medications for Neuralgia Treatment
Anticonvulsant Medicines
Carbamazepine
Oxcarbazepine
Topiramate
Gabapentin
Pregabalin
Clonazepam
Phenytoin
Lamotrigine
Valproic acid
Tricyclic Antidepressants
Amitriptyline
Nortriptyline
Surgeries for Neuralgia Treatment
Balloon Compression
Glycerol Injection
Radiofrequency Thermal Lesioning
Stereotactic Radiosurgery
Microvascular Decompression
Complementary Approaches for Neuralgia Treatment (in combination with medications)
To know more about the Neuralgia Treatment Market Trends, visit this link- https://www.factmr.com/report/2282/neuralgia-treatment-market

Based on distribution channel, the global Neuralgia Treatment market is segmented as:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Others
Neuralgia Treatment Market: Overview

Overall incidence estimates for various neuralgias conditions are as follows: 4.3/100,000/year for Trigeminal Neuralgia, 3.3/100,000/year for Postherpetic Neuralgia, 0.7/100,000/year for Glossopharyngeal Neuralgia, and 3.2/100,000/year for Occipital Neuralgia. Based on such indices, the Neuralgia Treatment market is poised to grow at a significant rate. In the Neuralgia Treatment market, pharmacologic agents will remain as the primary line of treatment for many. The most common neuralgias that drive the Neuralgia Treatment market include trigeminal, postherpetic, glossopharyngeal, and occipital neuralgia. These neuralgias differ in their pathophysiology, topography, complications, and treatment approach, necessitating awareness amongst individuals.

Neuralgia Treatment Market: Regional Outlook

Globally, North America, which includes the U.S., is expected to majorly contribute to the Neuralgia Treatment market. Aggressive healthcare investments and increasing awareness among people about Neuralgia Treatments will contribute to the growth of this region’s market. Asia Pacific is anticipated to have the second-largest market share in the Neuralgia Treatment market, primarily due to the largest geriatric population in the world present in China, India, and Japan. In addition, improved living conditions and better health care initiatives by governing bodies will also fuel the growth of the Neuralgia Treatment market. Europe, with its rising prevalence of chronic pain disorders in its developed and developing countries, will be the third-largest contributor to the Neuralgia Treatment market. Latin America and the Middle East & Africa are expected to show considerable growth in the neuralgias market in the near future, thanks to some of the developed and emerging economies such as GCC countries, Brazil, and Mexico, which are evolving with good healthcare governance.

Neuralgia Treatment Market: Key Players

Some of the key players operating in the global neuralgias market are Allergan Plc, Merz Pharma GmbH & Co., Biogen, Inc., Merz Pharma GmbH & Co., Abbott Laboratories, Trigemina Inc., Pfizer Inc., Novartis, GlaxoSmithKline Plc. F, Lupin, and others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.

Neuralgia Treatment Market Report is available for Pre-booking – https://www.factmr.com/checkout/2282/S

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at- https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuralgia Treatment Market Expected to Witness Rapid Expansion by the End of 2022 With Competition Tracking- Allergan, Merz Pharma GmbH & Co., Biogen, Merz Pharma GmbH & Co., Abbott Laboratories, Trigemina, Pfizer, Novartis, GlaxoSmithKline Plc. F, Lupin here

News-ID: 1364299 • Views:

More Releases from Fact.MR

Halloumi Cheese Market Surges Past US$ 1.2 Billion Mark by 2033, Fueled by 10.4% CAGR
04-19-2024 | Food & Beverage
Fact.MR
Halloumi Cheese Market Surges Past US$ 1.2 Billion Mark by 2033, Fueled by 10.4% …
It is anticipated that halloumi cheese market will be valued at US$ 445 million in 2023 and surpass US$ 1.2 billion by the end of 2033. It is projected that the worldwide market for halloumi cheese will grow at an astounding rate of 10.4% CAGR till 2033. Cyprus, a Middle Eastern nation, is the birthplace of halloumi cheese, which has been made there by local farmers for generations. Since this nation
Cheese Market Is Anticipated To Reach US$ 133 Billion At A CAGR Of 3.7% By 2032: Fact.MR Report
Cheese Market Is Anticipated To Reach US$ 133 Billion At A CAGR Of 3.7% By 2032: …
In 2022, the global cheese market held a value of US$ 92 billion, with projections indicating a substantial growth trajectory. By the end of 2032, it is anticipated to soar to US$ 133 billion, according to a study conducted by Fact.MR. The research suggests that the worldwide demand for cheese is expected to experience a steady increase, with a compound annual growth rate (CAGR) of 3.7% forecasted through the year
Product Engineering Services Market Is Set To Reach A Valuation Of US$ 2,400 Billion By 2033: Fact.MR Report
Product Engineering Services Market Is Set To Reach A Valuation Of US$ 2,400 Bil …
As of 2023, the global market for product engineering services reached a valuation of US$ 1,200 billion, with a projected growth to US$ 2,400 billion by the end of 2033. Forecasts indicate a steady increase in global demand for these services, with a compound annual growth rate (CAGR) expected to reach 7.2% from 2023 to 2033. The Product Engineering Services Industry sales study offers a comprehensive analysis on diverse features including
Golf Shoes Market Is Anticipated To Reach US$ 13,331.7 Million By 2032: Fact.MR Report
Golf Shoes Market Is Anticipated To Reach US$ 13,331.7 Million By 2032: Fact.MR …
In 2022, the worldwide golf shoes market is projected to be valued at US$ 8,584.1 million. It's anticipated to grow steadily at a compound annual growth rate (CAGR) of 4.4%, reaching US$ 13,331.7 million by 2032. The Golf Shoes Industry sales study offers a comprehensive analysis on diverse features including production capacities, Golf Shoes demand, product developments, sales revenue generation and Golf Shoes market outlook across the globe. market research report by

All 5 Releases


More Releases for Neuralgia

Trigeminal Neuralgia - Drug Pipeline Landscape, 2022
Trigeminal Neuralgia (TN), also known as tic douloureux, is a condition that causes painful sensations similar to an electric shock on one side of the face. The pain typically involves the lower face and jaw, although sometimes it affects the area around the nose and above the eye. There are two types of TN primary and secondary. Primary trigeminal Neuralgia has been linked to the compression of the nerve. Trigeminal Neuralgia
Trigeminal Neuralgia Treatment Market Opportunity Analysis, to 2026
Trigeminal neuralgia (TN), also known as tic douloureux, is a chronic pain disorder that affects the fifth cranial or trigeminal nerve. It causes inflammatory conditions due to systemic diseases including Lyme disease, sarcoidosis, and multiple sclerosis. There is also an association with collagen vascular diseases including systemic lupus erythematosus and scleroderma. The condition is treated on an outpatient basis, except till neurosurgical intervention is required. Its management must be customized
Trigeminal Neuralgia Treatment Market - Global Industry Insights, 2026
Trigeminal neuralgia (TN), also known as tic douloureux, is a chronic pain disorder that affects the fifth cranial or trigeminal nerve. It causes inflammatory conditions due to systemic diseases including Lyme disease, sarcoidosis, and multiple sclerosis. There is also an association with collagen vascular diseases including systemic lupus erythematosus and scleroderma. The condition is treated on an outpatient basis, except till neurosurgical intervention is required. Its management must be customized
Trigeminal Neuralgia - Pipeline Review, H1 2018
"The Report Trigeminal Neuralgia - Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Trigeminal Neuralgia Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Pipeline Review, H1 2018, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape. Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1581021 Trigeminal neuralgia is a chronic pain
Postherpetic Neuralgia - Pipeline Insight and Therapeutic Assessment Reviewed, 2 …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Postherpetic Neuralgia-Pipeline Insight, 2017” to its report offerings. The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265519 The report provides comprehensive insights of the ongoing therapeutic research and development across Postherpetic Neuralgia. The report provides a complete understanding of the pipeline activities covering all
Trigeminal Neuralgia Market Rugged Expansion Foreseen by 2021
Trigeminal neuralgia occurs when the functioning of the trigeminal nerve is disrupted due to damage of the nerve. Trigeminal neuralgia is a chronic condition resulting in intense and extreme pain in the face and is more common among females. The incident represents electrical shock-like feeling and lasts from few seconds to minutes. The etiology of trigeminal neuralgia includes compression of blood vessels, degeneration of arteries, myelin sheath infiltration and idiopathic. To